Biotech · Private company
Ridgeback Biotherapeutics, LP
Track this companyFree. Adds Ridgeback Biotherapeutics, LP to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- EIDD-2801Phase 2 · SARS-CoV 2ClinicalTrials.gov · fetched Nov 12, 2026
- Molnupiravir 200 mgPhase 2 · SARS-CoV-2 Infection, COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Molnupiravir 400 mgPhase 2 · SARS-CoV-2 Infection, COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Molnupiravir 800 mgPhase 2 · SARS-CoV-2 Infection, COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19PHASE2 · COMPLETED · started Jun 19, 2020ClinicalTrials.gov NCT04405570 · fetched Nov 12, 2026
- The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)PHASE2 · COMPLETED · started Jun 16, 2020ClinicalTrials.gov NCT04405739 · fetched Nov 12, 2026